TipRanks on MSN1d
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies
I-Mab is a U.S.-based global biotechnology company focused on developing innovative immunotherapies for cancer treatment, ...
Pharma stocks fall as Trump picks vaccine skeptic Robert F. Kennedy Jr. for US health job
Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...
FOX13 Memphis1d
MSCS joins class action lawsuit against drugmakers over insulin prices
Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...
Waukegan D60 joining suit to recover insulin charges; ‘No rhyme or reason for these increases other than price-gouging’
The District 60 Board of Education unanimously approved a resolution hiring the Frantz Law Group Tuesday at the Lincoln Center administration building in Waukegan to help it recoup some of the ...
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Los Angeles Times2d
Health stocks slide as Trump picks vaccine skeptic Kennedy
London-listed GSK Plc and France’s Sanofi SA saw similar declines, with Deutsche Bank analyst Emmanuel Papadakis cutting his ...
Managed Healthcare Executive2d
FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
MSCS joins 'mass action' suit against drug companies over insulin costs
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...